Finoriq research workspace
Zura Bio Ltd (ZURA) Insider Transactions & Form 4 Activity
Track insider acquisitions, dispositions, options, RSUs, and Form 4 activity for Zura Bio Ltd (ZURA).
Company Snapshot
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880), a fully human immunoglobulin G4 monoclonal antibody targeting interleukin-33 that has completed Phase 1 clinical studies; and Crebankitug (ZB-168), a fully human immunoglobulin G1 monoclonal antibody targeting interleukin-7 receptor alpha that has completed Phase 1 clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada.
- Company
- Zura Bio Ltd (ZURA)
- Ticker
- ZURA
- Market Cap
- $501.6M
- Latest Price
- $5.28
- Industry
- Biotech & Pharma
Zura Bio Ltd (ZURA) Recent Insider Transactions
Recent market insider transaction records indexed for Zura Bio Ltd (ZURA).
| Insider | Code | Value | Transaction Date |
|---|---|---|---|
| AI Biotechnology LLCClass A Ordinary Shares | P | Acquired | $12.5M | 2026-02-26 |
| Access Industries Holdings LLCClass A Ordinary Shares | P | Acquired | $12.5M | 2026-02-26 |
| ACCESS INDUSTRIES MANAGEMENT, LLCClass A Ordinary Shares | P | Acquired | $12.5M | 2026-02-26 |
| Blavatnik LenClass A Ordinary Shares | P | Acquired | $12.5M | 2026-02-26 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.